An experimental new weight loss pill from Danish pharmaceutical giant Novo Nordisk could be twice as effective as its blockbuster Ozempic and Wegovy jabs, early results from a small trial have suggested, sending the firm's shares soaring.
The drug amycretin caused people to lose 13 percent of their body weight over three months, according to the results of a phase one trial announced by the company.
ncG1vNJzZmivp6x7rbHAnZyrZZOWua16wqikaKaVrMBwusCtoKimkaF8r7HWZq6eoZedwW64zqyqZqiZobluuc6rnGadlpuypMDIr5xmrJiWu2672Z6kqaGTYruwws5mpaiqlJ7ArHvAq6uim5yarHeukXKcaWuTYrGkf5dmbHCeZmKGc4OYZnBubGhmgKWxwZ%2BdmmaYqbqt